Literature DB >> 3812621

Compliance with topical timolol treatment.

M A Kass, M Gordon, R E Morley, D W Meltzer, J J Goldberg.   

Abstract

To determine if compliance with timolol treatment was better than compliance with pilocarpine treatment (as reported previously), we measured compliance with timolol treatment in a sample of 110 patients using an unobtrusive eyedrop medication monitor, which recorded electronically the date and time of each drug administration over a four- to six-week period. The patients administered a mean +/- S.D. of 82.7% +/- 19.0% of the prescribed timolol doses (range, 20% to 100%). Forty-five patients were treated concurrently with timolol and pilocarpine. These patients administered a mean +/- S.D. of 84.3% +/- 14.0% of the prescribed timolol doses and 77.7% +/- 18.7% of the prescribed pilocarpine doses (P = .012, van der Waerden test). Our results suggest that while compliance is influenced by the drug regimen, defaulting is not eliminated by prescribing a more convenient medication with fewer side effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3812621     DOI: 10.1016/s0002-9394(14)74225-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  41 in total

1.  Glaucoma screening: too little, too late?

Authors:  A Sommer
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

2.  Patients prefer once-daily glaucoma drops.

Authors:  Alex J Buller; Laurence H Morgan; Brian L Hercules
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02       Impact factor: 3.117

3.  Impact of a health communication intervention to improve glaucoma treatment adherence. Results of the interactive study to increase glaucoma adherence to treatment trial.

Authors:  Karen Glanz; Allen D Beck; Lucja Bundy; Susan Primo; Michael J Lynn; Julia Cleveland; Jessica A Wold; Katharina V Echt
Journal:  Arch Ophthalmol       Date:  2012-10

4.  Microprocessor controlled compliance monitor for eye drop medication.

Authors:  M M Hermann; M Diestelhorst
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

5.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  The electronic medication event monitor. Lessons for pharmacotherapy.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

7.  Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom.

Authors:  Z Zhou; R Althin; B S Sforzolini; R Dhawan
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

8.  Treatment for glaucoma: adherence by the elderly.

Authors:  J H Gurwitz; R J Glynn; M Monane; D E Everitt; D Gilden; N Smith; J Avorn
Journal:  Am J Public Health       Date:  1993-05       Impact factor: 9.308

9.  An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite.

Authors:  David Granet; Steven J Lichtenstein; Bruce Onofrey; James A Katz
Journal:  Clin Ophthalmol       Date:  2007-12

10.  First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.

Authors:  Philippe Denis; Christophe Baudouin; Alain Bron; Jean-Philippe Nordmann; Jean Paul Renard; Jean François Rouland; Eric Sellem; Mourad Amrane
Journal:  BMC Ophthalmol       Date:  2010-02-24       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.